Nomogram based on human epididymis protein 4 predicted concurrent endometrial cancer for patients diagnosed with atypical endometrial hyperplasia before surgery

Yaochen Lou, Xiaojun Chen, Jun Guan2024 · DOI

Introduction

Atypical endometrial hyperplasia (AEH) represents a critical juncture in gynecologic health, often serving as a precursor to endometrial cancer (EC). However, the diagnostic path is frequently complicated by the presence of "hidden" malignancies. Research indicates that nearly 30% of patients diagnosed with AEH preoperatively are found to have concurrent EC during their definitive hysterectomy. This diagnostic gap presents a major clinical hurdle: if cancer is not suspected beforehand, the initial surgery may be incomplete—lacking essential steps like lymph node staging. Such omissions can lead to suboptimal patient management, delayed adjuvant therapies, and potentially poorer long-term outcomes. Consequently, there is an urgent need for preoperative tools that can accurately predict the presence of concurrent EC in patients initially diagnosed with AEH.

Methodology

This retrospective study analyzed 455 patients diagnosed with preoperative AEH who underwent hysterectomy at a tertiary hospital between January 2020 and December 2022. The researchers aimed to determine if preoperative levels of human epididymis protein 4 (HE4) could predict the presence of concurrent EC.

Using a multivariate logistic regression model, the team identified independent predictive factors. These factors were then used to construct a nomogram—a graphical tool designed to estimate the probability of concurrent EC for individual patients. The model's reliability was assessed through internal validation using a bootstrap resampling method.

Key Findings

The study confirmed that concurrent EC is a prevalent issue, occurring in 23.4% of the cohort.

The Role of HE4

Preoperative HE4 levels were significantly higher in patients with concurrent EC compared to those with confirmed AEH (median 50.5 pmol/L vs. 43.7 pmol/L, p < 0.001). Receiver operating characteristic (ROC) analysis demonstrated that HE4 has strong predictive potential:

  • Concurrent EC: AUC = 0.696 (95% CI = 0.633–0.760)
  • Intermediate-to-High-Risk EC: AUC = 0.713 (95% CI = 0.563–0.863)

Independent Risk Factors

Multivariate analysis identified three primary independent predictors for concurrent malignancy:

  1. Postmenopausal Status: (OR = 5.25)
  2. HE4 Level: (OR = 3.84)
  3. Body Mass Index (BMI): (OR = 2.09)

Nomogram Performance

By combining these three factors, the researchers developed a nomogram that outperformed any single predictor. The bootstrap-corrected concordance index (C-index) for the nomogram was 0.725 (95% CI = 0.665–0.784). The model showed high consistency between predicted probabilities and observed clinical outcomes, suggesting significant potential for clinical utility.

Clinical Implications

The development of this HE4-based nomogram represents a significant step toward personalized surgical planning in gynecologic oncology. By moving beyond a "one-size-fits-all" approach to AEH, clinicians can now leverage a combination of biochemical markers and patient demographics to assess risk. The synergy between HE4, BMI, and menopausal status captures a broader picture of the patient's physiological state than any single metric.

In practice, this tool allows for a more aggressive, cancer-appropriate surgical approach to be planned from the outset for high-risk individuals. This proactive strategy minimizes the psychological and physical burden of repeat surgeries on patients and ensures that those with concurrent EC receive the full standard of care without delay. While the study's retrospective nature and single-center data suggest the need for future external validation, the current results provide a strong foundation for improving the preoperative stratification of AEH patients.

Conclusion

Preoperative HE4 is a valuable biomarker for identifying concurrent endometrial cancer in patients initially diagnosed with AEH. The developed nomogram, incorporating HE4, postmenopausal status, and BMI, offers a practical and effective tool for improving surgical strategy and patient management in gynecologic oncology.

Summary updated

Abstract

Objective: Almost 30% of patients diagnosed with atypical endometrial hyperplasia before surgery (preoperative-AEH) are found to have concurrent endometrial cancer (EC) at definitive hysterectomy, leading to incomplete primary surgery and delayed adjuvant treatment.This study aimed to investigate whether preoperative level of human epididymis protein 4 (HE4) could predict concurrent EC for preoperative-AEH patients and help to establish a nomogram for better clinical management.Methods: Preoperative-AEH patients who underwent hysterectomy in a tertiary hospital from January 2020 to December 2022 were retrospectively analyzed.Independent predictive factors determined by multivariate logistic regression model were used to establish nomogram and internal validation was performed by a bootstrap resampling method.Results: A total of 455 preoperative-AEH patients were included, 23.4% of whom had concurrent EC.HE4 level significantly increased in concurrent-EC patients compared with finaldiagnosed AEH patients (median 50.5 vs. 43.7 pmol/L, p<0.001).Receiver operating characteristic curve also showed good predictive potential of HE4 for concurrent EC (area under the receiver operating characteristic curve [AUC]=0.696;95% confidence interval [CI]=0.633-0.760;p<0.001) and concurrent intermediate-high-risk EC (AUC=0.713;95% CI=0.563-0.863;p=0.005).Multivariate analysis revealed the independent predictive factors for concurrent EC were HE4 level (odds ratio [OR]=3.84;95% CI=2.07-7.13),postmenopausal status (OR=5.25;95% CI=2.26-12.22)and body mass index (BMI, OR=2.09; 95% CI=1.12-3.91).The 3 factors were used to create the nomogram that showed a better goodness-of-fit for predicting concurrent EC.The bootstrap-corrected of concordance index of nomogram was 0.725 (95% CI=0.665-0.784),which was higher than that of each factor alone.The nomogram also displayed good consistency between the probabilities and observed values and potential clinical usefulness.Conclusion: HE4 showed good predictive potential for concurrent EC in preoperative-AEH patients.The nomogram based on HE4, postmenopausal status and BMI might improve this predictive value to stratify high-risk patients for better clinical strategy.
BibTeX
@misc{lou2024nomogram,
  author = {Yaochen Lou and Xiaojun Chen and Jun Guan},
  title = {{Nomogram based on human epididymis protein 4 predicted concurrent endometrial cancer for patients diagnosed with atypical endometrial hyperplasia before surgery}},
  year = {2024},
  doi = {10.3802/jgo.2024.35.s1.0001},
}
Figure